Cardiovascular Toxicology is a pivotal journal dedicated to advancing the understanding of the interplay between toxic substances and cardiovascular health. Published by HUMANA PRESS INC, this journal serves as a critical resource for researchers and professionals in the fields of cardiology, toxicology, and molecular biology. With an ISSN of 1530-7905 and an E-ISSN of 1559-0259, it has established itself as a key source of high-quality research since its inception in 2001, continuing to contribute valuable insights through 2024. The journal enjoys a robust reputation, evidenced by its Q2 ranking in both Cardiology and Cardiovascular Medicine and Toxicology, along with a Q3 ranking in Molecular Biology for 2023. With Scopus rankings placing it in the 80th percentile for Cardiology and 71st for Toxicology, Cardiovascular Toxicology attracts submissions that reflect cutting-edge research and innovative methodologies. Notably, the journal prioritizes stringent peer review and scholarly rigor, ensuring that published works significantly impact the understanding of cardiovascular responses to various toxic agents. Though not an open-access journal, its content remains highly sought after in a diverse scholarly community, making it indispensable for those dedicated to enhancing cardiovascular disease prevention, diagnosis, and treatment through toxicological insights.

Human Genomics, published by BMC, is a leading open-access journal dedicated to advancing the field of genomics and its applications in health and disease. Since its inception in 2003, the journal has provided a vital platform for researchers to disseminate groundbreaking findings related to genetic research, contributing significantly to areas such as Drug Discovery, Genetics, Molecular Biology, and Molecular Medicine, as reflected in its Q1 and Q2 quartile rankings throughout 2023. With an ISSN of 1473-9542 and an E-ISSN of 1479-7364, Human Genomics not only delivers high-quality, peer-reviewed research but also ensures accessibility to a broader audience, empowering professionals, students, and academics to stay at the forefront of genomic science. Through its rigorous editorial standards and impactful publications, the journal fosters a collaborative environment for innovative research across the globe from its base in the United Kingdom. By promoting open access since its launch, Human Genomics continues to enhance the visibility and impact of genetic studies, making it an essential resource for anyone involved in the rapidly evolving field of human genomics.

Chemical Research in Toxicology is a premier journal published by the American Chemical Society, dedicated to advancing the understanding of toxicological effects associated with chemical substances. Since its inception in 1988, this esteemed journal has maintained a robust impact factor, ranking in the Q1 quartile for both Medicine (miscellaneous) and Toxicology as of 2023, reflecting its significance and influence in the fields of pharmacology and toxicology. With an impressive Scopus ranking at #16 out of 133 in the Toxicology category, it serves as a vital resource for researchers, professionals, and students seeking cutting-edge insights and scholarly articles that bridge the gap between chemistry and toxicological science. Although not an open-access publication, it continues to provide comprehensive analyses and original research that inform safe chemical practices and regulatory policies, further enhancing its role in public health and safety.

Epigenetics, published by Taylor & Francis Inc, is a leading journal in the fields of Cancer Research, Medicine (miscellaneous), and Molecular Biology. With an ISSN of 1559-2294 and an E-ISSN of 1559-2308, this journal has been paving the way for groundbreaking research since its inception in 2006, and it continues to play a crucial role in advancing our understanding of epigenetic mechanisms and their implications in health and disease. The journal is highly regarded, ranking in the Q1 category for Medicine and Q2 for both Cancer Research and Molecular Biology according to the 2023 category quartiles. Researchers and professionals in the field will find invaluable insights and innovative studies within its pages, making it an essential resource for those engaged in cutting-edge research. Although the journal is not open access, it encourages a comprehensive understanding through high-quality peer-reviewed content. With its creative exploration of the epigenetic landscape, Epigenetics serves as a vital platform for the sharing of knowledge that could lead to breakthroughs in treatments and therapies.

GENETICS AND MOLECULAR BIOLOGY, published by the SOC BRASIL GENETICA, is a prominent journal dedicated to the advancement of knowledge in the fields of genetics and molecular biology. Since its inception in 1998, this Open Access journal has served as a vital platform for researchers, professionals, and students to disseminate their findings and engage with the latest innovations and discoveries. With an impact factor that reflects its growing influence, GENETICS AND MOLECULAR BIOLOGY ranks in the Q3 category for both genetics and molecular biology as of 2023, indicating its position within the academic community. The journal is indexed in Scopus, highlighting its commitment to maintaining rigorous peer-review standards while providing wide-reaching access to quality research. Operating out of Ribeirão Preto, Brazil, it fosters a collaborative environment for academic discourse and research development not only in Brazil but also globally. The journal encourages submissions that explore a wide range of topics in genetics and molecular biology, making it an essential resource for anyone involved in these dynamic fields.

MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, published by Elsevier, is a renowned journal that explores critical advancements in the field of genetic toxicology and environmental mutagenesis. With an ISSN of 1383-5718 and an E-ISSN of 1879-3592, it ranks in Q3 for Genetics and Q2 for Health, Toxicology, and Mutagenesis as of 2023. This journal not only emphasizes the importance of environmental factors in genetic material alterations but also disseminates significant research findings that aid in understanding the implications for public health and safety. Operating from Amsterdam, Netherlands, it serves as a pivotal platform for researchers, professionals, and students, fostering an informed community keen on evolving the parameters of genetic research. Although it currently does not offer open access, the journal's commitment to high-quality peer-reviewed content ensures substantial contributions to the academic literature, enhancing our comprehension of mutagenic processes and their environmental triggers.

MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH, published by Elsevier, stands as a premier journal in the fields of Genetics and Health, Toxicology and Mutagenesis, boasting a Q1 ranking in both categories for 2023. With an impressive impact factor and rigorous peer-review process, this journal serves as a vital platform for disseminating cutting-edge research and comprehensive reviews regarding the implications of genetic mutations and related health effects. Established in the Netherlands, it has evolved from its inception in the early 1990s to become an essential resource for researchers, professionals, and students alike, facilitating advancements in the understanding of mutation research. Despite not offering an open-access model, the journal ensures a wide reach through institutional subscriptions, emphasizing its commitment to fostering scholarly dialogue and promoting significant findings within the scientific community.

Epigenomics is a leading journal in the realms of Cancer Research and Genetics, published by Future Medicine Ltd in the United Kingdom. With an ISSN of 1750-1911 and an E-ISSN of 1750-192X, the journal has been an integral part of the scientific community since its inception in 2009, and is set to converge its impactful research publications through 2024. The journal occupies a significant position in its category quartiles as evidenced by its ranking—Q3 in Cancer Research and Q2 in Genetics as of 2023. With Scopus rankings of #138/347 in Genetics and #113/230 in Cancer Research, it demonstrates scholarly excellence and is recognized for its contributions to understanding the role of epigenetic modifications in health and disease. While Epigenomics operates under traditional subscription models, it remains a vital resource for researchers, professionals, and students eager to explore the complex interplay between genes and the epigenome. The journal's innovative approach to epigenetics and its impact on cancer research makes it essential reading for those at the forefront of biomedical research.

GENOMICS is a prestigious journal published by Academic Press Inc Elsevier Science, dedicated to advancing the field of genetic research and molecular biology. With an impressive impact factor, this journal is recognized for its rigorous peer-review process and high-quality publications that cover a wide range of topics within the genomics discipline. Operating from the United States, GENOMICS has established itself as a vital resource for researchers, professionals, and students alike, standing at Q2 in the Genetics category according to the latest rankings. With a rich history dating back to 1987 and convergence extending to 2024, the journal highlights cutting-edge discoveries and methodologies, ensuring that its readership remains at the forefront of genetic advancements. Although currently not an open-access journal, articles published within its pages are often accessible through various academic platforms, enhancing worldwide reach and dissemination. For those engaged in the fields of biochemistry, genetics, and molecular biology, GENOMICS serves as an indispensable platform for impactful research and collaborative initiatives.

Breast Cancer Research and Treatment, published by Springer, stands as a pivotal journal within the domains of Cancer Research and Oncology, exemplified by its impressive Q2 and Q1 quartile rankings, respectively, in the 2023 category rankings. Since its inception in 1981, this journal has provided a vital platform for disseminating cutting-edge research focused on all aspects of breast cancer, ranging from molecular biology to treatment strategies. With an ISSN of 0167-6806 and E-ISSN of 1573-7217, it captures a broad audience of researchers, clinicians, and students dedicated to improving patient outcomes. The journal emphasizes high-quality, peer-reviewed studies that pave the way for advancements in therapy and direct novel insights into oncological practices. By maintaining a strong ranking in Scopus with percentile placements of 74th in Oncology and 61st in Cancer Research, Brest Cancer Research and Treatment continues to foster innovation and collaboration in the fight against breast cancer.